Start Submission Become a Reviewer

Reading: Graves' orbitopathy treated with immunosuppressive therapy and orbital radiotherapy in a ter...

Download

A- A+
dyslexia friendly

Case Reports

Graves' orbitopathy treated with immunosuppressive therapy and orbital radiotherapy in a tertiary care endocrine centre: case series

Authors:

D. C. Kottahachchi ,

North Colombo Teaching Hospital, Ragama, LK
About D. C.
Diabetes and Endocrine Unit
X close

W. K. M. G. Amarawardena,

North Colombo Teaching Hospital, Ragama, LK
About W. K. M. G.
Diabetes and Endocrine Unit
X close

N. A. S. Ariyawansa,

North Colombo Teaching Hospital, Ragama, LK
About N. A. S.
Diabetes and Endocrine Unit
X close

S. Siyambalapitiya,

North Colombo Teaching Hospital, Ragama, LK
About S.
Diabetes and Endocrine Unit
X close

K. A. Perera

National Cancer Institute, Maharagama, LK
X close

Abstract

Graves’ Orbitopathy (GO) is a localized entity of Graves’ disease, which is a challenging disease to treat. We describe 6 cases of moderate to severe GO who presented to our endocrine centre, with a mean age of 48.6 years and equal gender distribution. All of them were thyrotoxic before the presentation and were treated with antithyroid drugs. CT scans of orbits in 5 patients were consistent with GO. All of the patients were treated with intravenous methylprednisolone pulse therapy for a duration of 12 weeks and orbital radiotherapy for two weeks according to European Groups on Graves' Orbitopathy (EUGOGO) guideline. All six patients went into remission and remained so after one year of follow-up. Combination therapy seems to be effective in treating moderate to severe GO.
How to Cite: Kottahachchi, D.C. et al., (2016). Graves' orbitopathy treated with immunosuppressive therapy and orbital radiotherapy in a tertiary care endocrine centre: case series. Sri Lanka Journal of Diabetes Endocrinology and Metabolism. 6(2), pp.40–45. DOI: http://doi.org/10.4038/sjdem.v6i2.7314
Published on 29 Aug 2016.
Peer Reviewed

Downloads

  • PDF (EN)

    comments powered by Disqus